不同种族和民族患者高肿瘤突变负荷、高微卫星不稳定及错配修复缺陷的分子特征:来自多机构子宫内膜癌分子靶向治疗联盟(ECMT2)的真实世界数据
本研究基于多机构子宫内膜癌分子靶向治疗联盟的真实世界数据,纳入742例子宫内膜癌患者,分析高肿瘤突变负荷(TMB-H)、高微卫星不稳定(MSI-H)及错配修复缺陷(dMMR)的种族/民族分布及临床特征。结果显示22%患者生物标志物阳性,非西班牙裔黑人患者阳性率仅9%,显著低于其他种族/民族的26%。生物标志物阳性与较低死亡风险相关(aHR 0.63,95%CI 0.46-0.88),作者认为需前瞻性研究阐明这些分子差异对治疗和结局的影响。
要点
- 742例子宫内膜癌患者中22%为生物标志物阳性,其中12%同时TMB-H和MSI-H/dMMR。
- 非西班牙裔黑人患者生物标志物阳性率仅9%,其他种族/民族患者为26%。
- 生物标志物阳性与较低死亡风险相关(aHR 0.63,95%CI 0.46-0.88)。
核心结论
- 不到10%的非西班牙裔黑人子宫内膜癌患者具有TMB-H和/或MSI-H/dMMR,生物标志物阳性与生存改善相关。
- 作者认为需要前瞻性研究阐明这些分子差异如何影响治疗和结局。
研究设计与样本
- 子宫内膜癌分子靶向治疗联盟为经中心核实的临床和分子数据库。
- 纳入接受肿瘤分子谱分析的子宫内膜癌患者,共742例。
- TMB-H定义为每兆碱基≥10-12个突变。
- MSI-H通过下一代测序或聚合酶链反应确定,dMMR通过免疫组化检测MLH1、MSH2、MSH6或PMS2缺失确定。
- 肿瘤生物标志物阳性定义为TMB-H和/或MSI-H/dMMR。
主要发现
- 742例患者中22%(n=164)为生物标志物阳性。
- 12%(n=87)同时具有TMB-H和MSI-H/dMMR,8%(n=63)仅MSI-H/dMMR,2%(n=14)仅TMB-H。
- 非西班牙裔黑人患者中仅9%为生物标志物阳性,其他种族/民族患者为26%。
- 致病性POLE突变罕见(<1%,n=5)。
- TMB-H患者中高风险组织学类型比例为43%,MSI-H/dMMR患者为24%。
局限性
- 作者认为需要前瞻性研究阐明这些分子差异如何影响治疗和结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mismatch repair deficiency (dMMR), high microsatellite instability (MSI-H), and high tumor mutation burden (TMB-H) are predictive and prognostic biomarkers in endometrial cancer. We aimed to characterize the racial/ethnic distribution of molecular markers and the clinical characteristics among endometrial cancer patients with TMB-H and MSI-H/dMMR. METHODS: The Endometrial Cancer Molecularly Targeted Therapy Consortium is a centrally verified clinical and molecular repository. Patients with endometrial cancer who underwent tumor profiling were included. TMB-H was defined as ≥10-12 mutations per megabase. MSI-H was determined by next-generation sequencing or polymerase chain reaction, and dMMR by loss of MLH1, MSH2, MSH6, or PMS2 on immunohistochemistry. Tumor biomarker positivity was defined as TMB-H and/or MSI-H/dMMR. Overall survival was assessed using Kaplan-Meier and Cox proportional hazard models. RESULTS: Among 742 patients, 22 % (n = 164) were biomarker positive: 12 % (n = 87) had both TMB-H and MSI-H/dMMR, 8 % (n = 63) had MSI-H/dMMR alone, and 2 % (n = 14) had 14 TMB-H alone. Only 9 % of non-Hispanic Black patients had biomarker positive tumors compared to 26 % of patients from other racial/ethnic groups. Pathogenic POLE mutations were rare (<1 %, n = 5). Patients with TMB-H had a higher proportion of high-risk histologies (43 %) than those with MSI-H/dMMR (24 %). Biomarker positive tumors were associated with a lower risk of death compared to biomarker negative tumors (aHR 0.63, 95 % CI: 0.46, 0.88). CONCLUSION: Less than 10 % of non-Hispanic Black patients with endometrial cancer had TMB-H and/or MSI-H/dMMR, and biomarker positivity was associated with improved survival. Prospective studies are necessary to elucidate how these molecular differences impact treatment and outcomes.
引用
- Lee SS, Secord AA, Friedman S, et al. Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2). Gynecol Oncol. 2025. PMID: 40651147. doi:10.1016/j.ygyno.2025.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。